Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 20/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 18/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617119 | 1.00 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751356 | 0.94 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25783441 | 0.93 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461734 | 0.93 | MAPKAPK5 (0.63) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461613 | 0.92 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461611 | 0.92 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL29215942 | 0.92 | MAPKAPK5 (0.55) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25783513 | 0.92 | MAPKAPK5 (0.63) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461592 | 0.91 | MAPKAPK5 (0.61) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461594 | 0.91 | MAPKAPK5 (0.61) | MAPKAPK5MAPK14MAPK1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117120430-A | MK2 inhibitors and uses thereof | 新特拉有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230286950-A1 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023001282-A1 | HETEROCYCLE-SUBSTITUTED PYRIMIDINE DERIVATIVE | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| CN-115484952-A | Methods, compositions, and crystalline forms of substituted pyridone-pyridyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220235025-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022109481-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021195475-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-3845529-A1 | METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845529-A1 | METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3003039-B1 | METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3003039-B1 | METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2021-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
| US-20220235025-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPK14 152/4885MAPK1 178/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 69/4885MAPK14 211/4885MAPK1 244/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | MAPKAPK5 3641/4885MAPK14 3707/4885MAPK1 2515/4885 |
| US-20230286950-A1 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PDXK, DHPS, HCCS | MAPKAPK5 1249/4885MAPK14 714/4885MAPK1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.